Roche's immune checkpoint inhibitor tiragolumab, in combination with Tecentriq, failed to meet the primary endpoint of overall survival in the Phase III SKYSCRAPER-01 trial for lung cancer.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing